Enzyme Inhibitors for Breast Cancer Therapy
Pp. 204-227 (24)
Hariharan Jayaraman, Praveen Kumar Posa Krishnamoorthy, Lakshmi Suresh, Mahalakshmi Varadan, Aparna Madan and Balu Ranganathan
Globally millions of women die of cancer, the most common cancer
occurrence sites for women being breast, cervical and ovarian. Engineered enzyme
inhibitors are a component of the drug regimen that has taken a drive into
pharmaceutical international corporations’ product portfolios which is by targeted
delivery, moderating disease-free survival and leading to procrastination of death.
Since 2002 the enzyme inhibitor anastrozole (Arimidex) is used as the first drug of
choice for breast cancer which is available in the commercial market. Currently, there
are several other FDA approved enzyme inhibitors like sulfonanilide analogs available
in the pharmaceutical shelf decreasing aromatase expression and regulating enzyme
activity for the treatment and cure of breast cancer.
Anastrozole, Breast cancer, Celecoxib, Enzyme inhibitors, HSD17B,
Palms Connect Sdn Bhd, Shah Alam 40460, Selangor Darul Ehsan, Malaysia